Showing results (401-410 of 427) with videos related to

Sort By:
Pageof 43
Blood|January 9, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosisIlaria Crespiatico, Mattia Zaghi, Cristina Mastini, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Cancer|June 24, 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CMLMario Tiribelli, Roberto Latagliata, Massimo Breccia, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 43